- Current report filing (8-K)
27 April 2010 - 11:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 21, 2010
Angiotech Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
British Columbia
|
|
000-30334
|
|
98-0226269
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
1618 Station Street
Vancouver, BC, Canada V6A 1B6
(Address of principal executive offices)
(604) 221-7676
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 1.01.
|
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
|
On April 21, 2010, Angiotech Pharmaceuticals, Inc. (Angiotech) and certain U.S. subsidiaries of Angiotech (the Borrowers)
entered into an amendment (the Amendment) to the Credit Agreement, dated as of February 27, 2009 (as previously amended, the Credit Agreement), with Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), as
arranger, administrative agent and lender. Angiotech and certain other of Angiotechs subsidiaries guaranty the payment and performance of the Borrowers obligations under the Credit Agreement and have entered into a Consent and
Reaffirmation with respect to the Amendment. Capitalized terms used herein and not otherwise defined have the meaning given to them in the Credit Agreement.
Among other things, the Amendment permits various intercompany transactions, expands the definition of Permitted Liens and amends the definition of
EBITDA. The Amendment also reduces, until the fourth quarter of 2011, the minimum EBITDA and fixed charge coverage ratio that Angiotech is required to maintain.
The above description of the Amendment does not purport to be a complete statement of the parties rights and obligations under the Credit
Agreement, as amended by the Amendment. The above description of the Amendment is qualified in its entirety by reference to the Amendment, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by
reference. Any information disclosed in this Current Report on Form 8-K or the exhibits hereto shall not be construed as an admission that such information is material.
ITEM 9.01.
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
|
|
|
Exhibit
Number
|
|
Description
|
10.1
|
|
Third Amendment to Credit Agreement, dated as of April 21, 2010, by and among Angiotech, as Parent, the subsidiaries of Parent listed as borrowers on the signature pages thereto,
as borrowers, the lenders signatory thereto, as lenders, and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), as arranger and administrative agent.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Angiotech Pharmaceuticals, Inc.
(Registrant)
|
|
|
|
|
Date: April 27, 2010
|
|
|
|
By:
|
|
/s/ Jay Dent
|
|
|
|
|
|
|
|
|
Jay Dent
Senior Vice
President, Finance
|
INDEX TO EXHIBITS
|
|
|
Exhibit
Number
|
|
Description
|
10.1
|
|
Third Amendment to Credit Agreement, dated as of April 21, 2010, by and among Angiotech, as Parent, the subsidiaries of Parent listed as borrowers on the signature pages thereto,
as borrowers, the lenders signatory thereto, as lenders, and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), as arranger and administrative agent.
|
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Sep 2023 bis Sep 2024